Welcome to our dedicated page for XCELERATE news (Ticker: XCRT), a resource for investors and traders seeking the latest updates and insights on XCELERATE stock.
XCELERATE INC (XCRT) is a healthcare services and products company that focuses on integrating innovative technologies into the medical field. Established with a mission to revolutionize clinical care through the application of advanced engineering and intellectual property, Xcelerate operates in three main business areas:
- Medical Technology and Virtual Health Services: Xcelerate is dedicated to extending the reach of physicians through AI and virtual health technology, especially targeting patients in developing countries.
- Consumer Health and Beauty Products: The company formulates, packages, and markets clinically tested health and beauty products, including the Ceramedx® line, which features plant-based ceramide therapy for dry and sensitive skin.
- Owning and Licensing Medical Equipment: Xcelerate holds and licenses various forms of medical equipment and a portfolio of patents and technology licenses.
Notable achievements include the recent publication of two utility patent applications by the United States Patent and Trademark Office, and the company's selection as an approved vendor for the Army & Air Force Exchange Service. Xcelerate is also actively involved in enhancing investor relations with the help of Darrow Associates and has partnered with Craft Capital Management to facilitate capital raising and advisory services.
With its headquarters in Mauldin, SC, Xcelerate is poised for significant growth and continues to develop its diverse range of healthcare solutions to improve global medical care.
Xcelerate, Inc. (OTC PINK: XCRT) provides a shareholder update highlighting significant achievements in 2021, including achieving reporting status and acquiring a controlling interest in AfiyaSasa Africa. The company plans to launch the ASA program in Africa, aiming to connect physicians with patients via mobile devices amidst a growing market of mobile users. Additionally, Xcelerate is pursuing two provisional patents related to medical power tools and robotic telesurgery. A Reg. A Tier 2 filing is underway to support these initiatives, marking a promising start to 2022.
Xcelerate, Inc. (OTC pink sheets: XCRT) announced on January 3, 2022, that it has acquired a 51% stake in AfiyaSasa Africa, LLC, a medical technology and virtual health company. This acquisition aims to enhance healthcare access in developing regions by utilizing AI and Augmented Reality to connect patients with physicians remotely. The ASA system facilitates initial check-ins and triage through mobile devices, utilizing medical devices linked to phones for effective telemedicine. This partnership with ASA, co-founded by Dr. Dilan Ellegala, is expected to improve healthcare delivery for millions in Africa.
Xcelerate, Inc. (OTC: XCRT) has signed a Definitive Memorandum of Understanding with HS Pharmaceuticals, LLC to acquire 100% of its membership interests and a 51% interest in HS Cosmetics, Inc. This agreement includes provisions for drafting an Acquisition Agreement with a pre-determined valuation and capital raising efforts to support HS Pharmaceuticals' intellectual property development and HS Cosmetics' marketing strategy initiated in April 2021. CEO Michael O'Shea noted collaboration with Network1 Financial to facilitate these financial activities.
Xcelerate, Inc. (OTC Pink Sheets: XCRT) announced the completion of its Consolidated Annual Financial Statements audit for FY 2019 and FY 2020, conducted by BF Borgers CPA PC, a PCAOB registered firm. This achievement is a significant step towards the company's objective to uplist to OTCQB or QX, eventually aiming for a national exchange. The company focuses on acquiring and commercializing medical innovations, combining them with early-stage med tech enterprises.
Xcelerate (OTC Pink Sheets: XCRT) has engaged BF Borgers CPA PC for auditing its financial statements for the fiscal years ending December 31, 2019, and 2020. This move aligns with the company's goal to enhance shareholder value, according to CEO Michael O'Shea. Additionally, the management is exploring potential acquisition candidates, aiming for future growth. While no agreements are in place yet, there is optimism about success. Xcelerate plans to raise funds for business capital and pursue uplisting to OTCQB or QX, with hopes of eventually achieving a NASDAQ listing.
Xcelerate, Inc. (OTC: XCRT) has entered into two investment banking agreements with a prominent New York-based firm to facilitate acquisition financing. This firm, established in the late 1980s, manages over $2.8 billion in retail accounts. Xcelerate will leverage this partnership to support its aggressive acquisition strategy as it identifies potential targets. The company's CEO, Michael O'Shea, expressed confidence that these agreements validate their business plan and will accelerate growth.
Xcelerate, Inc. (OTC: XCRT) announced that Nobel Prize winner Dr. Barry Marshall discussed the company's mission to enhance medical technology during a global broadcast on ticker NEWS. Dr. Marshall, who serves on Xcelerate's Advisory Board, emphasized the benefits of working with an American public company, particularly in funding. He aims to identify investment opportunities in Australia for Xcelerate. CEO Michael O'Shea highlighted Dr. Marshall's contributions and the importance of increasing public awareness to support investment and medical communities.
Xcelerate, Inc. (OTC pink sheets: XCRT) announced signing a non-binding letter of intent (LOI) to explore a business combination with HS Pharmaceuticals, LLC, based in Greenville, SC. HS Pharmaceuticals has a platform of patented technologies focusing on immunotherapy alternatives and infection treatment. Xcelerate aims to leverage HS’s research and intellectual property through due diligence led by its team of clinicians and researchers. This strategic move underscores Xcelerate's commitment to innovative acquisitions in early-stage medical technology.
Xcelerate, a leader in early-stage medical technology, announced on May 3, 2021, the removal of the 'Yield' sign from its stock symbol by OTC Markets, achieving 'Pink Current Reporting' status. This change enhances corporate transparency and allows investors better access to company information. CEO Michael O'Shea expressed enthusiasm for this milestone, emphasizing ongoing efforts to maintain compliance and improve corporate standing. Additionally, the company is exploring innovative acquisitions in the patent and engineering sectors to further its growth.
Xcelerate, Inc. (OTC: XCRT) has launched a new website, www.xcelerate.global, highlighting its innovative role in integrating advanced engineering solutions with MedTech and clinical care. The website aims to communicate the company's mission, progress, and potential within the MedTech sector, serving as a platform for updates and news. CEO Michael O'Shea emphasized that the global domain reflects the company’s aspirations for international growth and collaboration. Xcelerate focuses on acquiring patents and engineering technologies and is committed to advancing early-stage medical technologies.
FAQ
What is the current stock price of XCELERATE (XCRT)?
What is the market cap of XCELERATE (XCRT)?
What does Xcelerate Inc. do?
How does Xcelerate contribute to healthcare?
What recent patents has Xcelerate published?
What are the key product lines of Xcelerate?
Who are Xcelerate's strategic partners?
Where is Xcelerate's headquarters located?
What is the significance of Xcelerate's partnership with the Army & Air Force Exchange Service?
How does Xcelerate plan to grow its business?
What are the company’s financial goals?
How can investors stay updated on Xcelerate's developments?
